Advances in Molecular Pathology, Diagnosis, and Treatment of Amyotrophic Lateral Sclerosis

Overview

Journal BMJ

Specialty General Medicine

Date 2023 Oct 27

PMID 37890889

Authors

Hristelina Ilieva

Mithila Vullaganti

Justin Kwan

Affiliations

Soon will be listed here.

Abstract

Although the past two decades have produced exciting discoveries in the genetics and pathology of amyotrophic lateral sclerosis (ALS), progress in developing an effective therapy remains slow. This review summarizes the critical discoveries and outlines the advances in disease characterization, diagnosis, imaging, and biomarkers, along with the current status of approaches to ALS care and treatment. Additional knowledge of the factors driving disease progression and heterogeneity will hopefully soon transform the care for patients with ALS into an individualized, multi-prong approach able to prevent disease progression sufficiently to allow for a dignified life with limited disability.

Citing Articles

T1-relaxation times along the corticospinal tract as a diagnostic marker in patients with amyotrophic lateral sclerosis.

Dierksen F, Geibel J, Albrecht J, Hofer S, Dechent P, Hesse A Front Neuroimaging. 2025; 4:1549727.

PMID: 40017821 PMC: 11865248. DOI: 10.3389/fnimg.2025.1549727.

Re-Analyses of Samples From Amyotrophic Lateral Sclerosis Patients and Controls Identify Many Novel Small RNAs With Diagnostic And Prognostic Potential.

Loher P, Londin E, Ilieva H, Pasinelli P, Rigoutsos I Mol Neurobiol. 2025; .

PMID: 39982687 DOI: 10.1007/s12035-025-04747-2.

Complex Genetic Framework in Familial Amyotrophic Lateral Sclerosis With a C9ORF72 Mutation: A Case Report.

Frolov A, Dsa E, Henderson C, Guzman M, Hayat G, Martin 3rd J Cureus. 2025; 16(12):e76027.

PMID: 39835009 PMC: 11743604. DOI: 10.7759/cureus.76027.

Effectiveness and safety of traditional Chinese therapies intreating patients with amyotrophic lateral sclerosis: a protocol for systematic review and meta-analysis.

Li R, Bao T, Li B, Xia P, Zhang T, Zhang H Front Neurol. 2025; 15():1519513.

PMID: 39811452 PMC: 11730076. DOI: 10.3389/fneur.2024.1519513.

Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.

Moss K, Saxena S Cells. 2025; 14(1).

PMID: 39791748 PMC: 11719703. DOI: 10.3390/cells14010047.

References

Woolley S, York M, Moore D, Strutt A, Murphy J, Schulz P . Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler. 2010; 11(3):303-11. DOI: 10.3109/17482961003727954. View

Abrahams S, Newton J, Niven E, Foley J, Bak T . Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 15(1-2):9-14. DOI: 10.3109/21678421.2013.805784. View

Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand B, de Haan R . The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2015; 87(6):611-9. DOI: 10.1136/jnnp-2015-310734. View

Renton A, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs J . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72(2):257-68. PMC: 3200438. DOI: 10.1016/j.neuron.2011.09.010. View

Prudlo J, Bissbort C, Glass A, Grossmann A, Hauenstein K, Benecke R . White matter pathology in ALS and lower motor neuron ALS variants: a diffusion tensor imaging study using tract-based spatial statistics. J Neurol. 2012; 259(9):1848-59. DOI: 10.1007/s00415-012-6420-y. View

Alshikho M, Zurcher N, Loggia M, Cernasov P, Reynolds B, Pijanowski O . Integrated magnetic resonance imaging and [ C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018; 83(6):1186-1197. PMC: 6105567. DOI: 10.1002/ana.25251. View

Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S . The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2011; 83(1):102-8. DOI: 10.1136/jnnp-2011-300188. View

Douaud G, Filippini N, Knight S, Talbot K, Turner M . Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain. 2011; 134(Pt 12):3470-9. DOI: 10.1093/brain/awr279. View

Gallo V, Wark P, Jenab M, Pearce N, Brayne C, Vermeulen R . Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. 2013; 80(9):829-38. PMC: 3598455. DOI: 10.1212/WNL.0b013e3182840689. View

10.

Omer T, Finegan E, Hutchinson S, Doherty M, Vajda A, McLaughlin R . Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(7-8):611-623. DOI: 10.1080/21678421.2017.1332077. View

11.

Filippini N, Douaud G, Mackay C, Knight S, Talbot K, Turner M . Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. 2010; 75(18):1645-52. PMC: 2974368. DOI: 10.1212/WNL.0b013e3181fb84d1. View

12.

Verstraete E, Veldink J, van den Berg L, van den Heuvel M . Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis. Hum Brain Mapp. 2013; 35(4):1351-61. PMC: 6869230. DOI: 10.1002/hbm.22258. View

13.

Paganoni S, Macklin E, Hendrix S, Berry J, Elliott M, Maiser S . Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020; 383(10):919-930. PMC: 9134321. DOI: 10.1056/NEJMoa1916945. View

14.

Shefner J, Cudkowicz M, Zhang H, Schoenfeld D, Jillapalli D . The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve. 2004; 30(4):463-9. DOI: 10.1002/mus.20120. View

15.

Zhang Y, Schuff N, Woolley S, Chiang G, Boreta L, Laxamana J . Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study. Amyotroph Lateral Scler. 2011; 12(6):421-9. PMC: 3804304. DOI: 10.3109/17482968.2011.593036. View

16.

van Zundert B, Brown Jr R . Silencing strategies for therapy of SOD1-mediated ALS. Neurosci Lett. 2016; 636:32-39. DOI: 10.1016/j.neulet.2016.07.059. View

17.

Chio A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M . Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019; 93(10):e984-e994. PMC: 6745732. DOI: 10.1212/WNL.0000000000008063. View

18.

Ratai E, Alshikho M, Zurcher N, Loggia M, Cebulla C, Cernasov P . Integrated imaging of [C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy H-MRS in amyotrophic lateral sclerosis. Neuroimage Clin. 2018; 20:357-364. PMC: 6092554. DOI: 10.1016/j.nicl.2018.08.007. View

19.

Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen W, van den Berg L . The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS. Neurology. 2012; 79(13):1377-83. DOI: 10.1212/WNL.0b013e31826c1aa1. View

20.

Christidi F, Karavasilis E, Ferentinos P, Xirou S, Velonakis G, Rentzos M . Investigating the neuroanatomical substrate of pathological laughing and crying in amyotrophic lateral sclerosis with multimodal neuroimaging techniques. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 19(1-2):12-20. DOI: 10.1080/21678421.2017.1386689. View